Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study seeks to compare the effectiveness of two medications used to treat opioid use
disorder, extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX),
among adults currently incarcerated in U.S. jails and prisons at 5 distinct trial sites. This
open-label, non-inferiority, head-to-head study design will offer providers, correctional and
public health authorities, payers and policy makers' timely and relevant data to assess the
effectiveness of XR-B (and XR-NTX) as potentially useful re-entry and relapse prevention
treatment options. It is hypothesized that XR-B is non-inferior to XR-NTX when comparing
retention-in-study-medication treatment options.